COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
20/10/2025
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this year NDA submission [...]
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU
20/10/2025
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One ® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (Nasdaq: EDAP) (“EDAP” or the “Company”) , a global [...]
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
20/10/2025
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- [...]
PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair
20/10/2025
Seasoned corporate director brings extensive expertise in audit, accounting, and internal controls Fourth independent director to join the board since 2024 DELRAY BEACH, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PetMed [...]
NewGen Announces Strategic Entry into Art Tokenization Market with $2 Million Private Collection Deal, Expandable to $200 Million
20/10/2025
BANGKOK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through [...]
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
20/10/2025
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment [...]
Clene to Present at the Emerging Growth Conference
20/10/2025
SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Humber River Health Celebrates 10-Year Anniversary of Wilson Site
20/10/2025
Built on a vision of being lean, green and digital TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Humber River Health proudly marks the 10 th anniversary of its Wilson Site, a decade since opening North America’s first [...]
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
20/10/2025
Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission ( UPCR ≤0.5 g/g) achieved in one-third of patients and [...]
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
20/10/2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
20/10/2025
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
20/10/2025
New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain — and can reshape the future of research and drug development for Alzheimer’s, Parkinson’s, and other [...]
J-Star Applauds the Cooperation of Nasdaq and Ho Chi Minh City to Develop an International Financial Center in Vietnam
20/10/2025
TAICHUNG CITY, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/10/2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
BioCryst to Report Third Quarter 2025 Financial Results on November 3
20/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, [...]
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
20/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon [...]
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
20/10/2025
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher ( [...]
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
20/10/2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
20/10/2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Pages